Targeting the AR–RUNX2 interaction presents an opportunity for the development of novel therapeutic approaches that would retain expression of
androgen-stimulated tumor suppressors while preventing synergistic interaction between AR and RUNX2 at prostate cancer–driving genes. Such novel therapeutic approaches would be particularly suited to prevent disease recurrence in patients whose primary tumor biopsies exhibit high expression of AR, RUNX2, and SNAI2.